Last reviewed · How we verify
SOLE
At a glance
| Generic name | SOLE |
|---|---|
| Sponsor | The University of Texas Health Science Center, Houston |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
- Erythema (local)
- Swelling (local)
- Pruritus (local)
- Tenderness (local)
- Pain (local)
- Erythema (local, lower range)
- Swelling (local, lower range)
- Pruritus (local, lower range)
- Tenderness (local, lower range)
- Pain (local, lower range)
- Systemic reactions (rush immunotherapy)
- Systemic reactions (conventional immunotherapy)
Serious adverse events
- Shock
- Laryngeal edema
- Hypotension
- Angioedema
- Wheezing
- Urticaria
- Generalized skin erythema
- Rhinitis
- Systemic reactions (fatal)
Key clinical trials
- Establishment and Evaluation of Standardized Clinical, Biological and Imaging Parameters to Assess the Response of LDRT in Heel Spur With Plantar Fasciitis
- Toward Ubiquitous Lower Limb Exoskeleton Use in Children and Young Adults
- Effect of Exoskeleton-Assisted Walking on Gait Parameters in Healthy Adults (NA)
- Regional Associations Between Q-Angle and Plantar Loading in Active Young Adults
- Efficacy, Safety, and Tolerability, of EN3835 vs Placebo in the Treatment of Plantar Fibromatosis (PHASE2)
- Three Fraction Accelerated Partial Breast Irradiation as the Sole Method of Radiation Therapy for Low-risk Stage 0 and I Breast Carcinoma (NA)
- A Single-Blind Randomized Controlled Study Comparing the Efficacy of High-Intensity Laser Therapy and Focused Extracorporeal Shock Wave Therapy in Patients With Plantar Fasciitis (NA)
- Glyceryl Trinitrate Gel Phonophoresis on Planter Fasciiatis (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SOLE CI brief — competitive landscape report
- SOLE updates RSS · CI watch RSS
- The University of Texas Health Science Center, Houston portfolio CI